Determinants of stock-outs of first line anti-tuberculosis drugs: the case of public health facilities of Addis Ababa city administration health bureau, Addis Ababa, Ethiopia

Kassech Sintayehu1,2, Eden Dagnachew Zeleke3*, Busha Temesgen4, Meron Kifle5, Dawit Getachew Assefa5, Kibebe Zenebe6, Ashenafi Kassahun7 and Ben Tegegn Yimer8

Abstract

Background: The health sectors success has been determined by consistent and reasonably priced health commodities supply. Despite possible death from the disease, Tuberculosis (TB) can be prevented with early diagnosis and appropriate treatment for which enough, effective, and qualified medicines need to be available. However, studies revealed stock of anti-TB drugs in health facilities. Here we present the recent finding on determinants of stock out of Anti-TB drug at public health facilities of Addis Ababa.

Objective: This study aimed to identify determinants of stock outs of first line anti TB drugs at public health facilities under Addis Ababa City Administration Health Bureau.

Method: Mixed study design were employed. A total of 106 facilities were included in the sampling frame and data were collected from the study population such as drug store managers of health facilities providing TB treatment using semi structured questionnaire and through in-depth interview with Addis Ababa hubs of the Ethiopian Pharmaceuticals Supply Agency (EPSA), Addis Ababa City Administration Health Bureau and selected heads of pharmacy departments of health facilities from May 1–30, 2020 considering one year back retrospective data from March 20,2019 to March 20,2020. Structured record review of data from Logistics Management Information System (LMIS) tools having TB drugs was done using structured observation checklist. Data were entered, cleaned, and analyzed using SPSS Version 20. Both descriptive and multiple logistic regression analysis were performed.

Result: 52(62.7%) of health facilities encountered stock out for at least one of these drugs during the past 1 year; Rifampicin 75 mg + Isoniazid 50 mg (RH 75/50 mg) were most stocked out first line anti-TB drug from 33(39.8%) of facilities with 17 mean stocks out days while Rifampicin 75 mg + Isoniazid 50 mg + Pyrazinamide 150 mg (RHZ 75/50/150 mg) were the least first line anti-TB drug stocked out from facilities with mean 5 days of stock out. Delayed supply of anti TB drug from EPSA, delivery of reduced quantity of anti TB drugs by EPSA and stocked out of anti TB
Background
Tuberculosis (TB) have been among the top 10 causes of mortality. Globally, 10 million people have got the disease in which 151 new TB cases per 100,000 population reported in 2018 and Ethiopia is among the 30 high TB burden countries [1].

As per the Ethiopian Food and Drug Authority (EFDA), “safe, effective, and affordable medicines of the required and assured quality, in adequate quantity should always be available for the provision of proper healthcare service” [2].

The consequence of medicines stock out from health facilities has been reported by different studies. Such as discontinuation of treatment by patients, hopelessness in the health systems, extra cost, discouraging the clinicians, care givers, and providers [3, 4] high risk for drug resistance and adverse effects [4, 5] and subsequently, put many patients on higher risk of morbidity and mortality and confronting the public health [5, 6] and decrease TB cure rate and treatment success rate [7].

Previous study in 2016 showed > 80% availability of key medicine for infectious diseases in Ethiopia’s public health facilities [8] and recently conducted study on service readiness assessment shows <50% availability of most essential drugs [9]. A study at public health facilities of Addis Ababa showed availability of Anti TB drugs on the day of visit were 72.5% and 68% at the hospital and health center, respectively [10]. Most deaths from TB could be prevented with rapid diagnosis and appropriate treatment for which sufficient amount of effective and qualified medicines is required, hence TB control program should be conscious about the availability of Anti-TB drugs for proper implementation [11].

Studies determined different reasons for Stock-outs such as poor communication and coordination among stakeholders, poor inventory management practice [12] educational level of stock managers, poor practice of use of ICT by stock managers [13] poor availability of transportation and road infrastructure [4, 14] unexpected demand changes or fluctuations, limited health budgets, raw material problems, frequently changing regulatory requirements [15] and, supply of short expiry drugs from a supplying warehouse [16].

There has been contrariety between reports about the availability of infectious disease medicines and Addis Ababa city Administration health bureau report on stock out for TB medicines in public health facilities providing TB treatment services. Therefore, this study aimed to investigate the magnitude and determinant factors for stock out of first line anti TB drugs at public health facilities under Addis Ababa City Administration Health Bureau.

Methods and materials
Study design
Mixed design (quantitative and qualitative) were employed. In-depth interview and secondary data review was done.

Study area and period
Addis Ababa city is administratively subdivided into 10 sub-cities and has a total population of 3686, 068 million. From 104 public health facilities (98 health center and 6 public hospitals), all health centers and 4 hospitals were providing TB diagnostic and treatment services. The study period was from March 20, 2019 to March 20, 2020 and data collection time was from May 1–30, 2020. In this study retrospective collection of data on stock out situations in the previous one-year was done at the same time collecting data on determinants for stock-outs.

Source population
All public health facilities of Addis Ababa providing tuberculosis diagnosis and treatment services which totally were 102 health facilities, 2 Regional Health Bureau, 2 supplying pharmaceutical warehouses (EPSA hubs).

Study population
Drug store manager and heads of pharmacy department from public health facilities, TB/HIV and pharmaceutical logistics case team from regional health bureau and
program drugs distribution coordinator from the supplying pharmaceutical warehouses (EPSA hubs).

**Eligibility criteria**

**Inclusion criteria**

- Being head and store manager of the selected facility.
- The respondent should work on this position at least for 6 months.

**Study variables**

**Dependent variable**

✓ Anti-TB first line drug Stock out

**Independent variable**

✓ ICT
✓ Health system support
✓ Performance of supplying hub

**Sample size and sampling method**

A total of 106 respondents were targeted to be interviewed from 102 health facilities, regional health bureau and 2 supplying hubs. Census and non-probability sampling methods was applied to include all the eligible public health facilities providing TB treatment services in Addis Ababa. Study participants were selected based on the year of experience and their knowledge towards the topic.

**Data collection procedure and tool**

**Quantitative data collection methods**

Semi-structured questionnaire was administered to drug store managers at 102 health facilities and structured record review of data from Logistics Management Information System (LMIS) tools and bin card having TB drugs was done using structured observation checklist to extract stock out data for the for previous 1 year.

**Qualitative data collection methods**

Using in-depth interview with totally 5 heads of pharmacy departments, 2 program drugs distribution coordinators and 2 TB/HIV and pharmaceutical logistics case team. All the interview session were recorded, and personal identifiers were deidentified for the analysis.

The data collection questions for primary source and checklists for secondary data sources was adapted from tools of other researchers and Logistics System Assessment Tool (LSAT) respectively and indicators to measure stock-outs was utilized from Logistics Indicators Assessment Tool (LIAT) and tools developed by the pharmaceuticals fund and supply agency [17, 18].

**Data quality assurance**

Data collectors were trained by the principal investigator before the data collection initiated. A structured questionnaire and observational checklist were used to avoid bias. The tool was piloted and revised based on the finding accordingly. Data were checked for completeness on daily bases.

**Data analysis**

Data were entered, cleaned, and analyzed using SPSS Version 20. Both descriptive and multiple logistic regression analysis were performed. Assumptions were checked before regression analysis and p value less than 0.05 were considered statistically significant. Thematic analyses were performed for qualitative data analysis. Qualitative data was handled manually and categorized and individually coded with themes related to the variables and added as an explanation for the findings of quantitative analysis.

**Result**

It was planned to collect the data from all TB treatment providing facilities (102), however due to the COVID 19 pandemic, 14 of them were turned in to isolation center. The response rate was 83/88 (94.3%). From those participants, 40 (48.2%) and 43 (51.8%) were female and male respectively with mean (±SD) age of 31 (±5.51). Majority of the respondents 48 (57.8 %) hold a bachelor’s degree, 33 (39.8 %) diploma and 2 (2.4%) hold postgraduate degree. 46 (55.42%) of participant had (0-5 years of experience and 37 (44.58%) had 6-13 years of experience. Two participants from supply hub and two from regional health bureau were interviewed about determinant factor of stock out of first line Anti-TB drug.

**Stock out rate of first line anti-tuberculosis drugs**

The result revealed that 52 (62.7%) of health facilities encountered stock out for at least one of the first line anti TB drugs during the past 1 year. As shown in Table 1 RH 75/50mg (Rifampicin 75mg + Isoniazid 50mg) was most stocked out first line anti-TB drug from 33 (39.8%) of facilities with 17 mean stocks out days while RHZ 75/50/150mg (Rifampicin 75mg + Isoniazid 50mg + Pyrazinamide 150mg) was the least first line anti-TB drug stocked out from facilities with mean 5 days of stock out.

**Frequency of stock outs of first line anti-tuberculosis drugs**

Taking the average number of stock outs, the most frequently stock out was observed for INH 300mg (Isoniazid) (0.66 with a maximum of 6 times of stock outs with
a year) and followed by RH75/50 mg for which the mean frequency of 0.6 observed with maximum of 3 times of stock outs in the same period.

**Status of training of participants**

74(89.2%) of the participants have been trained on Integrated Pharmaceutical Logistics System (IPLS) while only 14(16.87) of participants took anti-TB Drug supply and Management (DSM) training.

**Determinants for stock outs of first line anti-TB drugs**

**Information and communication technology (ICT) practice of the facility**

As shown in Table 2, thirty-eight and twenty-six participants were agreeing and strongly agree respectively on the involvement of facility in the logistic social media group. Thirty-two and nineteen participants agreed and strongly about facility utilization of SMS for exchange of logistic information while twenty-one participant each agreed and strongly agreed on the utilization of internet for exchange of logistic information. Thirty-four and forty participants were agreeing and strongly agreed respectively for use of electronic Logistics Management Information System (LMIS) by the facility.

**Health system support activities at the health facility**

As shown on Table 3, majority of respondents (forty-nine of them agree and twenty-five of them strongly agree) had positive response about supportive supervision provided for their facility while twenty-five and fifty-seven respondents agree and strongly agree respectively about the drug store are managed by academically qualified staff. Regarding the existence of in-service training related to pharmaceuticals logistics management, forty-five and twenty-seven of participants were agreeing and strongly agreeing respectively. Thirty-three and forty-four of the participants agreed and strongly agreed respectively about the reliability of logistic data which were sent to Ethiopian Pharmaceuticals Supply Agency (EPSA) While thirty-two and forty-seven of them respectively agreed and strongly agreed on timely submission of Report and request form (RRF) to EPSA.

**Performance of the supplying hub (EPSA)**

As shown on Table 4, forty-one and twelve participants respectively agreed and strongly agreed about delayed supply of anti TB drug from EPSA while forty-eight and six respectively agreed and strongly agreed about ordered quantity of Anti-TB drugs reduced by EPSA. Thirty-six

---

### Table 1

Findings from Health Facilities on Stock out for each of first line anti TB Drugs as of March 20/2019 to March 20/2020

| First Line Anti TB drugs | Facilities stock Out n (%) | # Of Days of Stock Out Mean (range) |
|--------------------------|----------------------------|-----------------------------------|
| TB Patient Kit           | 21 (25.3%)                 | 12.93 (0–158)                     |
| RHZ 75/50/150 mg         | 14 (16.9%)                 | 5.22 (0–79)                       |
| RH 75/50 mg              | 33 (39.8)                  | 16.81 (0–128)                     |
| INH 300 mg               | 26 (31.3%)                 | 18.30 (0–203)                     |
| INH100 mg                | 16 (19.3%)                 | 9.84 (0–240)                      |
| Ethambutol 100 mg        | 25 (30.1%)                 | 24.24 (0–194)                     |

---

### Table 2

Information and communication technology (ICT) practice of the facility

| Items                                                   | Strongly Disagree | Disagree | Neutral | Agree | Strongly Agree |
|---------------------------------------------------------|-------------------|----------|---------|-------|----------------|
| Involvement of the facility in logistics social media group (Telegram, viber, WhatsApp) | 9 (10.9%)         | 4 (4.8%) | 6 (7.2%) | 38 (45.8%) | 26 (31.3%) |
| Practice of the facility using SMS for exchange of logistics information | 12 (14.5%)       | 16 (19.3%) | 4 (4.8%) | 32 (38.6%) | 19 (22.9%) |
| Use of internet by the facility for Exchanging logistics information | 18 (21.7%)       | 21 (25.3%) | 2 (2.4%) | 21 (25.3%) | 21 (25.3%) |
| Use of electronic LMIS by the facility                  | 4 (4.8%)          | 3 (3.6%) | 2 (2.4%) | 34 (41%)  | 40 (48.2%) |

### Table 3

Respondents perception towards health System Support Activities at the Health Facility

| Items                                                   | Strongly Disagree | Disagree | Neutral | Agree | Strongly Agree |
|---------------------------------------------------------|-------------------|----------|---------|-------|----------------|
| The facility received supportive supervision             | 2 (2.4%)          | 1 (1.2%) | 6 (7.2%) | 49 (59%) | 25 (30.1%) |
| Drug Store are Managed by academically qualified staff   | 0                 | 1 (1.2%) | 0       | 25 (30.1%) | 57 (68.7%) |
| Existence of in-service training related to pharmaceuticals logistics management | 4 (48%)          | 6 (7.2%) | 1 (1.2%) | 45 (54.2%) | 27 (32.5%) |
| Reliable logistics data sent to EPSA                     | 2 (2.4%)          | 0        | 4 (4.8%) | 33 (39.8%) | 44 (53%) |
| Pharmaceuticals are ordered by the facility without any bureaucracy | 3 (3.6%)         | 11 (13.3%) | 3 (3.6%) | 38 (45.8%) | 28 (33.7%) |
| RRF is timely submitted to EPSA                          | 0                 | 3 (3.6%) | 1 (1.2%) | 32 (38.6%) | 47 (56.6%) |
and twelve of participants agreed and strongly agreed respectively about stock out of Anti-TB drug in the previous year while thirty-eight and twelve of participants agreed and strongly agreed respectively on the short expiry date of Anti-TB drug supplied by EPSA.

Findings from logistic regression analysis
As shown on Table 5, delayed supply of Anti-TB drug from EPSA significantly increased stock out of at least one anti-TB drug by 10 times (10.34(2.167–49.329) at the health facilities. Stock out of at least one anti-TB drug from health facilities significantly increase by 11 times when EPSA reduced the quantity of anti-TB drug ordered and increase by 6 times when there were stock out at EPSA.

Findings from key informants in in-depth interview
Stock out of TB patient Kit and reasons for stock out:

➤ “TB patient Kit was stocked for about 3 months and the reason mainly was delay in shipment from the external supplier company and I think delay in payment from the country also contributed to the shipment delay” Key Informant 1 (KI 1)

➤ Even though all anti TB drugs should always be available at health facilities most of the health facilities were stocked out for pediatrics formulations and not manage it at all.

➤ “Tracer drugs including anti TB drugs should always be available at health facilities but there is knowledge gap at health facilities on identifying which anti TB Drugs to request especially new formulations such as new pediatrics formulations, even sometimes requests are made on already phased out formulations such as E400 mg and also newly introduced items were not captured by request and request formats ,thus some still use the old format and mistakenly request already phased out drugs and drop the one should be requested hence, most of the time stock outs reported were artificial” .KI 2

➤ “When you request responsible people at health facilities on availability of Pediatrics anti TB formulations, they mainly tell you that these items are stocked out, and they blame the supplying hub for this but, most of the time early requests on these items were not being placed because the number of pediatrics patients are small and arrive for treatment very intermittently. Hence, this created negligence at health facilities and attention was not being paid, and they tend to request these drugs after patient arrive to their facility, or they refer the patient to another facility which stocked these drugs claiming they don’t have the drug to start the treatment”. KI 3

➤ “Currently, we don’t have complete item for treating pediatrics patients, this is because there are not pediatrics cases at our facility but when a patient comes, we borrow from a nearby health facility and no patient has been made to leave without treatment.” KI 4

Table 4 Respondents perception towards performance of the Supplying Hub (EPSA)

| Items                                                                 | Strongly Disagree | Disagree | Neutral | Agree | Strongly Agree |
|----------------------------------------------------------------------|-------------------|----------|---------|-------|----------------|
| Delay of anti TB drug supply from EPSA                               | 3(3.6%)           | 21(25.3%)| 6(7.2%) | 41(49.4%) | 12(14.5%)     |
| EPSA supplies anti TB drugs reducing quantity Ordered                | 8(9.6%)           | 16(19.3%)| 5(6%)  | 48(57.8%) | 6(7.2%)       |
| There has been Stock out of anti TB Drugs at EPSA in the previous year| 13(15.7%)         | 17(20.5%)| 5(6%)  | 36(43.4%) | 12(14.5%)     |
| The Facility faces supply of short expiry anti TB drugs by EPSA      | 8(9.6%)           | 21(25.5%)| 6(7.2%) | 38(45.8%) | 10(12%)       |

Table 5 Logistic regression analysis

| Variables                                                                 | No | Yes | COR (10.866–141.173) | AOR (2.167–49.329) |
|---------------------------------------------------------------------------|----|-----|-----------------------|--------------------|
| Delay of anti TB drug supply from EPSA                                    | Yes| 53  | 39.167                | 10.34 (2.167–49.329) |
|                                                                            | No | 30  | 1                     | 1                  |
| EPSA supplies anti TB drugs reducing quantity Ordered                     | Yes| 54  | 32.229(9.247–112.325) | 11.452(2.183–60.079) |
|                                                                            | No | 29  | 1                     | 1                  |
| There has been Stock out of anti TB Drugs at EPSA in the previous year    | Yes| 48  | 5.700(2.159–15.049)   | 5.646(1.240–25.707) |
|                                                                            | No | 35  | 1                     | 1                  |
Discussion

The finding from this research revealed that 52 (62.7%) of health facilities encountered stock out for at least one of these drugs during the past 1 year. A national survey in south Africa showed stocked out rate during 2010/11 were 14.2% and 10.7% during 2012/13. Vhembe district had the highest stock out (41.1) during 2012/13 while A Nzo district (40.1%) during 2010/11 [19]. A recent study were also revealed 16.52% stock out of TB drug in northern cape [7]. The difference between stock out rate among different countries may be because of different approach of TB programs and time of study.

The finding from this study were much higher on the rate of stock out of TB patient kit 21 (25.3%) and Isoniazid 300 mg 26 (31.3%) than the study conducted on 2017 7% stock out for TB Patient Kit and 17.5% for Isoniazid 300 mg while showed lower stock out of pediatrics formulation [RH75/50 mg (33(39.8%)) and RHZ75/50 (14 (16.9%))] than RH75/50 mg and R HZ75/50; 57% and 82.5% respectively in the same study [10]. The higher level of stock out found by Mekonen in 2017 might be due to the transition to newer pediatrics formulations at the same period and the old formulations were under phaseout stage and due to transition time, most of the facilities encountered stock outs until the supplying hub delivers these drugs for all the health facilities [10].

Even if there was significant level of stock out, it is important to note that facility specific stockout does not necessarily imply that a patient does not receive treatment as health facilities have a practice of borrowing from nearby health facilities once patient comes and try to manage the patient [20].

There were different previous studies from other countries who have got the same result pertaining to supplier performance such as restock delay [4, 21] stock out at supplying hub [4, 22].

Stock out of medicine may have high impact and consequence on patients such as patients left the facility without medicine or provided with an incomplete regimen [23], risk of treatment interruption or discontinuation, catastrophic expenditure [24, 25] treatment failure and drug resistance and ultimately increased risk of illness and death [26, 27].

The major limitation of this study is related to the data source used for collection of the stock out data where secondary data sources, mainly bin cards were used and sometimes it was difficult to get updated bin cards which was resolved by triangulating data from paper based, electronic bin cards and further requesting the drug store managers.

Conclusion

Above median of public health facilities encountered stock out of first line anti-TB drug in Addis Ababa. Delayed supply of anti TB drug from EPSA, reduction of delivery quantity of anti TB drugs by EPSA and stocked out of anti TB Drugs at EPSA were significant determinate factor of stocked out of first line anti-TB drug from facilities.

EPSA and other responsible bodies shall work collaboratively to improve their service and ensure availability of adequate amount of Anti TB drug in health facilities.

Abbreviations

DSM: Drug Supply & Management; EFDA: Ethiopian Food and Drug Authority; EPSA: Ethiopian Pharmaceuticals Supply Agency; ICT: Information communication technology; IPI: Integrated Pharmaceutical Logistics System; KI: Key Informant; LIAT: Logistics Indicators Assessment Tool; LMIS: Logistics Management Information System; LSAT: Logistics System Assessment Tool; RRF: Report and request form; SMS: Short message service; TB: Tuberculosis.

Supplementary Information

The online version contains supplementary material available at https://doi.org/10.1186/s12913-022-08430-3.

Additional file 1.

Acknowledgments

Not applicable.

Authors’ contributions

KS developed the proposal and KS, and MK collected the data. KS and EDZ conducted the analyses, and KS, EDZ, BT, MK, DGA, KZ, AK, and BTY write the interpretation, discussion, and conclusion. KS, EDZ, BT, MK, DGA, KZ, AK, and BTY critically reviewed and edited the manuscript and BT supervise overall study. All authors read and approved the final manuscript.

Funding

This research did not receive any specific grant.

Availability of data and materials

All data generated or analyzed during this study are included in this published article.

Declarations

Ethics approval and consent to participate

The protocol of this study was approved by Addis Ababa University school of commerce Ethics committee. The study was carried out in accordance with relevant guidelines and regulations. Informed consent was obtained from all subjects.

Consent for publication

Not applicable.

Competing interests

Authors declare that they have no competing interests.

Author details

1 KNCV (Koninklijke Nederlandse Chemische Vereniging (Royal Dutch Chemical Association) Tuberculosis Foundation, Addis Ababa, Ethiopia. 2 Ethiopian food and drug Authority, Addis Ababa, Ethiopia. 3 Department of Midwifery, Institute of Health, Bule Hora University, POBox-22497/1000, Bule Hora, Ethiopia. 4 Department of Nursing, College of health science, Dilla University, Dilla, Ethiopia. 5 National Blood Bank Services, Addis Ababa, Ethiopia. 6 Ethiopian Pharmaceuticals Supply Agency, Addis Ababa, Ethiopia. 7 Addis Ababa City Administration Health Bureau, Addis Ababa, Ethiopia.
References

1. WHO. Global tuberculosis report 2021. Geneva: World Health Organization; 2021. Licence: CC-BY-NC-SA 3.0 IGO. 2021.

2. FMOH. National Essential Medicine List Fifth Edition Administration and Control authority of Ethiopia. 2015:1–37. Available from: https://www.pharmacy.gov.eth/nv2/sites/default/files/document-upload/151119-draft-neml-5th-ed-v13-final-clean.pdf

3. Masters SH, Burstein R, Decenso B, Moore K, Haakenstad A, Ikilezi C, et al. Pharmaceutical availability across levels of care: evidence from facility surveys in Ghana, Kenya, and Uganda. PLoS One. 2014;9(12):1–12.

4. ZUMA SM. The factors affecting availability of medicines in the Free State. 2013(June):1–108. Available from: http://uir.unisa.ac.za/bitstream/handle/10500/13331/dissertation_zuma_sm.pdf?sequence=1.

5. MSE. RuDASA, RHAP TAC, SAHIVSoc. Stop Stockouts: SSP Stockouts National Survey June 2016. 2016(June):1–83. Available from: https://www.groundup.org.za/media/uploads/documents/StopStockoutsSurvey2016.pdf

6. Kaakeh R, Sweet BV, Reilly C, Bush C, DeLoach S, Higgins B, et al. Impact of drug shortages on U.S. health systems. Am J Heal Pharm. 2011;68(19):1811–9. Available from: https://academic.oup.com/ajhp/article/68/19/1811/5129450.

7. Koomen LEM, Burger R, Van Doorslaer EKA. Effects and determinants of tuberculosis drug stockouts in South Africa. BMC Health Serv Res. 2019;19(1):1–10.

8. Food M and HA and CA of E. Assessment of the pharmaceutical sector in Ethiopia. Addis Ababa, Ethiopia: Ministry of Health and World Health Organization. 2017. Available from: https://apps.who.int/iris/handle/10665/69107

9. Institute EPH. Service availability and readiness assessment (SARA). Addis Ababa, Ethiopia: Ministry of Health and World Health Organization. Available from: http://www.ephi.gov.et

10. Melkonen Z. Assessment on the supply chain performance of anti-TB drugs in public health facilities under City government of Addis Ababa health bureau. 2017

11. World Health Organization. Global Tuberculosis Report 2017.

12. Mungu SS. Supply chain management practices and stock levels of essential drugs in public health facilities in Bungoma east Sub-County, Kenya 2013. Available from: http://hdl.handle.net/11295/63129.

13. Ashiru C, Awunyo-Vitor D. Determinants of Stock-Out in Retail Shops in Ghana: Evidence from Kumasi Metropolis. Mod Econ. 2014;05(13):1240–52. https://doi.org/10.4236/me.2014.513115.

14. Annan J, Oteng-Abayie EF, Darko E. An assessment of health commodities management practices in health care delivery in Ghana: the case of selected hospitals in Ashanti region-Ghana. Eur J Bus Soc Sci. 2009;3(8):78–103. Available from: http://www.ejbs.com/recent-aspx-7.

15. Organization WH. Medicines shortages: global approaches to addressing shortages of essential medicines in health systems. WHO Drug Inf. 2016;30(2):180–5.

16. Damtew D, Worku F, Tesfaye Y, Jemal A. Availability of lifesaving maternal and child health commodities and associated factors in public and private health facilities of Addis Ababa, Ethiopia. Heal Serv Res Manag Epidemiol. 2019;6;2333392810989235. Available from: http://journals.sagepub.com/doi/10.1177/23333928109892350.

17. USAID | DELIVER PROJECT TO 1. Logistics System Assessment Tool (LSAT). Arlington, Va USAID | Delv Proj Task Order 1. 2009(January).

18. USAID | DELIVER PROJECT TO 1. Logistics Indicators Assessment tool (LIAT). Arlington, Va USAID | DELIVER PROJECT TO 1. Logistics Indicators Assessment Tool (LIAT) 2008:1–44.

19. Seunanden T, Day C. The extent and impact of TB drug stock-out. South African Heal Rev. 2014;3(May):173–89.

20. Nditunze L, Makuza S, Amoroso C, Odhiambo J, Ntakirutimana E, Cedro L, et al. Assessment of essential medicines stock-outs at health centers in Bureera District in northern Rwanda. Rwanda J 2015;2(1):85 Available from http://www.plosone.org/lookup/index.html,r,10.17371/journal.pone.0212405.

21. Fredrick MW, Mutuwa W. Factors influencing frequent stock-outs of essential medicines in public health facilities in Kisii County, Kenya. J Bus Manag. 2016;18(10):63–75.

22. Vasconcellos LHR, Sampiao M. The stockouts study: an examination of the extent and the causes in the São Paulo supermarket sector: BAR. 2009;63(3):263–79.

23. Hwang B, Shroufi A, Gils T, Steele SJ, Grimsrud A, Boullé A, et al. Stockouts of antiretroviral and tuberculosis medicines in South Africa: a national cross-sectional survey. Yotebieng M, editor. PLoS One. 2019;14(3):e0212405 Available from: https://dx.plos.org/10.1371/journal.pone.0212405

24. Nachega JB, Hislop M, Dowdy DW, Lo M, Omer SB, Regensburg L, et al. Adherence to highly active antiretroviral therapy assessed by pharmacy claims predicts survival in HIV-infected South African adults. JAIDS. 2006;43(1):78–84 Available from: https://journals.lww.com/00126334-200609000-00013.

25. Veenstra N, Whiteside A, Laloo D, Gibbs A. Unplanned antiretroviral treatment interruptions in southern Africa: how should we be managing these? Global Health. 2010;6(1):4 Available from: http://globalizationandhealth.biomedcentral.com/articles/10.1186/1744-8603-6-4.

26. Bastard M, Sanchez-Paladilla E, Hewison C, Hayrapetyan A, Khurkhumal S, Varaine F, et al. Effects of treatment interruption patterns on treatment success among patients with multidrug-resistant tuberculosis in Armenia and Abkhazia. J Infect Dis. 2015;211(10):1607–15. Available from: https://academic.oup.com/jid/article-lookup/doi/10.1093/infdis/jiu551.

27. Pasquet A, Messou E, Gabillard D, Minga A, Depoulolosky A, Deuffic-Burban S, et al. Impact of drug stock-outs on death and retention to care among HIV-infected patients on combination antiretroviral therapy in Abidjan, Côte d’Ivoire. PLoS One. 2010;5(10):e13414.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.